Clinical studies indicate that Alzheimer's disease (AD) disproportionately affects women in both disease prevalence and rate of symptom progression, but the mechanisms underlying this sexual divergence are unknown. Although some have suggested this difference in risk is a reflection of the known differences in longevity between men and women, mounting clinical and preclinical evidence supports women also having intrinsic susceptibilities toward the disease. Although a number of potential risk factors have been hypothesized to mediate these differences, none have been definitively verified. In this review, we first summarize the epidemiologic studies of prevalence and incidence of AD among the sexes. Next, we discuss the most likely risk factors to date that interact with biological sex, including (1) genetic factors, (2) sex hormones (3) deviations in brain structure, (4) inflammation and microglia, and (5) and psychosocial stress responses. Overall, though differences in life span are likely to account for part of the divide between the sexes in AD prevalence, the abundance of preclinical and clinical evidence presented here suggests an increase in intrinsic AD risk for women. Therefore, future studies focusing on the underlying biological mechanisms for this phenomenon are needed to better understand AD pathogenesis in both sexes, with the eventual goal of sex-specific prevention and treatment strategies.
Introduction
Alzheimer's disease (AD) is a progressive neurodegenerative disease that affects 5.4 million Americans aged 65 or older and is the fifth leading cause of death in the US. Of these 5.4 million patients, 3.3 million (nearly 70%) were women (Alzheimer's Association, 2015, Hebert et al., 2013) , but the biological basis of the sex-based differences in AD onset and progression remain elusive (Hua et al., 2010) .
While a definitive cause has yet to be proven, scientists and physicians have developed both epidemiologic and biological explanations for this apparent increase in risk (Lin and Doraiswamy, 2014; Mielke et al., 2014; Riedel et al., 2016) . Clinicians and researchers have noted that in most populations around the world, women tend to outlive men so that the gap between the number of men and women in a population widens with advancing age (Brookmeyer et al., 1998; Hebert et al., 2001; Plassman et al., 2007; Seshadri et al., 1997) . Although prevalence and incidence are rates, and so the frequency of women or men would normally not impact these measures, advancing age is the strongest risk factor for AD, and so the increased frequency of women at the highest age groups increases the likelihood of AD being diagnosed. Thus, the greater frequency of women of the oldest ages also impacts women's risk profiles, since AD diagnoses double roughly every 5 years (Kukull et al., 2002) . Combined with hypotheses integrating the improved cardiovascular health profiles of men who live to greatly advanced ages (i.e., 85 years or older) (Carmelli et al., 1998) , many experts have concluded that the apparent differences in AD prevalence between men and women are due to the indirect consequences of greater female longevity.
While this view still remains widely held, many recent studies have demonstrated that there are age-and risk factor-matched increases in the incidence of developing AD in women, though previous results have been inconsistent (Bachman et al., 1993; Edland et al., 2002; Fiest et al., 2016; Hebert et al., 2001; Rocca et al., 1998) . These recent clinical (human) and preclinical studies (animal models) have led to some new hypotheses predicting a female-specific increase in AD risk based on intrinsic biological differences, including sex-specific genetic interactions Janicki et al., 2014; Ungar et al., 2014) , hormones and associated endocrinological changes with age (Morrison et al., 2006; Rocca et al., 2011) , sexual dimorphism in brain structures (Elbejjani et al., 2015; Mielke et al., 2014; Sampedro et al., 2015) , heightened inflammatory responses in women (Hanamsagar and Bilbo, 2016) , and sex by stress interactions (Bangasser et al., 2017) . Still, the collection of evidence necessary to validate one or more of these hypotheses is in its infancy, and so the perspectives of individual experts on this subject remain varied.
In this review, we summarize and evaluate both the epidemiologic and biological evidence explaining the sex difference in AD risk to better inform both researchers and clinicians on the issue. After reviewing the available evidence, we believe this review will demonstrate that while some of the sex differences observed in AD prevalence are due to differences in longevity, it is very plausible that other distinct biological mechanisms increase the risk and disease progression of AD in women. We hope to present the most recent data shaping expert perspectives, inspiring researchers to go in new directions, and driving development of future diagnostic tools and treatments for AD.
Epidemiologic perspective
Age remains the greatest risk factor for AD, and the prevalence of AD in populations aged 85 years and older is vastly increased when compared to other age ranges (Riedel et al., 2016) , with multiple studies showing that the incidence of AD rises exponentially after the sixth decade of life (Kukull et al., 2002; Masters et al., 2015) . Similar to this increase in disease diagnoses, there are more women aged 85 years or older than men in most global subpopulations (Fratiglioni et al., 2000) , meaning there are more women at greatest risk based on age. In addition, women outlive men by an average of 4.5 years (World Population Ageing, 2015) . Therefore, while the prevalence of AD is often reported to be higher for women compared to men due to the increase in risk by greater age, the relative increase in women living to more advanced ages makes it difficult to assess whether women also have an increased agedmatched risk of the disease (Brookmeyer et al., 1998; Hebert et al., 2001; Plassman et al., 2007; Seshadri et al., 1997) .
Reflecting this, the literature examining incidence has also yielded conflicting results, as some studies report higher ageadjusted numbers for women (Irvine et al., 2012; Seshadri et al., 1997) . In addition, some evidence suggests that disease progression is accelerated in women, such as imaging studies indicating that women with mild cognative impairment (MCI) and AD show greater memory impairment compared to males with the same diagnoses (Gale et al., 2016; Lin et al., 2015) . Still, other studies fail to find an association between incidence, progression, and sex (Bachman et al., 1993; Edland et al., 2002; Hebert et al., 2001; Rocca et al., 1998) or remain inconclusive (Fiest et al., 2016) .
The inconsistent findings between studies may be explained by many factors, such as (1) type of study (i.e., prospective cohort, retrospective cohort, cross-sectional analysis), (2) cultural differences affecting diet, exercise, and stress response strategies, (3) differences in inclusion/exclusion criteria, especially for comorbid diseases, (4) sample size and statistical power, and (5) differing methods of classifying and confirming AD diagnoses. This last factor is of particular importance as many different criteria have been used across studies. According to the NINCDS-ADRDA diagnostic criteria, which a majority of current AD studies use, a definitive diagnosis of AD can only be made postmortem while probable AD is routinely diagnosed clinically through the presentation of certain symptoms, such as memory loss, and the exclusion of other possible diagnoses, including vascular dementia, other neurodegenerative diseases, other neuropsychiatric diseases, or acute causes of dementia such as traumatic injury or stroke (Trojanowski and Revesz, 2007) . While the diagnoses of AD are verified with autopsies in some studies (Gustafson, 1987; Matyi et al., 2017; Miech et al., 2002; Zandi et al., 2002) , many others (Barnes et al., 2005 , Hebert et al., 2001 , Galasko et al., 1998 ) use a clinical diagnosis, which may categorize other dementia presentations incorrectly as being AD. In addition, the pre-AD diagnosis of MCI can complicate the timing of when the later diagnosis of AD is made, making the process of defining the age-of-onset for AD more variable. Furthermore, aging women without dementia and with early MCI and sex-matched quantities of Ab seem to have better verbal recall memory than their respective age-matched male counterparts, and as the diagnosis of later stage MCI and AD are partially dependent on this cognitive process, women receive the diagnosis of AD later than men and may not be classified as having MCI as readily; (Sundermann et al., 2016 (Sundermann et al., , 2017 . Finally, one would think that a higher age-specific incidence of AD dementia among women would translate to a higher incidence of MCI and subclinical AD. Yet, some data have found the opposite (Roberts et al., 2012) , and although this may be explained by the increased verbal memory reserve in women, possibly leading to later MCI diagnoses (Sundermann et al., 2016 (Sundermann et al., , 2017 , this paradox deserves careful investigation.
The culmination of these classification difficulties is apparent in a study looking at subjects from 2 longitudinal assessments on community dwelling elderly patients by Schneider et al. (Schneider et al., 2009) . When comparing autopsy results of 483 participants with a diagnosis of probable AD, MCI, or no cognitive impairment, they found that only 41.8% of patients had pathology consistent with an AD-only diagnosis. Of the remaining patients, 45.8% had mixed pathology with AD and vascular dementia or FTD-like findings, 6.2% were misclassified, and 6.2% had no pathologic markers of any of the studied dementias. Likewise, 29.4% of patients without cognitive impairment had signs of AD pathology, 8.8% had signs of mixed pathology with AD, 16.5% had infarcts or Lewy bodies, whereas only 45.3% had no significant pathologic findings (Schneider et al., 2009) . The findings in the cognitively unimpaired patients are generally concerning for our understanding of AD pathogenesis, but the results suggesting that a large portion of clinical diagnoses are not corroborated by pathology makes quantifying the actual incidence and prevalence of AD even more challenging. It is also interesting to note that the most often-cited study reporting statistically significant differences in incidence between men and women, the Cache County Memory Study, verified many of their probable AD diagnoses with autopsy (Matyi et al., 2017 , Miech et al., 2002 , Zandi et al., 2002 .
Further supporting the classification bias as an issue in determining the real incidence of AD in men and women, many studies have shown that vascular dementia, as well as Lewy body dementia, is more common in men (Ferencz and Gerritsen, 2015, Whitmer et al., 2005) , and because of the high occurrence of mixed pathology in clinical AD diagnoses, it could be suggested that more men with dementia are being incorrectly classified as having AD as the precipitating factor for their cognitive decline, thus overestimating the total population of men with AD, especially at younger ages where the sex difference in prevalence is not as apparent. Indeed, it has been suggested that one aspect of the enlarged gap in AD prevalence between sexes in patients aged 85 years and older is because men with vascular complications tend to die earlier, so that the remaining healthy males have reduced cardiovascular risk factors for AD (Whitmer et al., 2005) . In addition, it has been reported that men have better overall health at older ages than their female counterparts in terms of morbidity but not mortality (Graves et al., 2006) . Although these differences have been shown reproducibly, this argument for improved male health with older age is a double-edged sword, as it becomes unclear if AD diagnoses are overestimated in younger men due to increasing adverse cardiovascular events and possible misclassification of the resultant dementia.
For all these stated reasons, it is unsurprising that there remain large differences in the reported incidence of AD between men and women across studies. Perhaps, the single most petinent example of this discrepancy was found in a recent meta-analysis, where inclusion of 22 studies on sex differences revealed that "all estimates of incidence and prevalence were higher for females compared to males, though the differences were not statistically different" (Fiest et al., 2016) . Still, the relative narrowing of the incidence rates compared to prevalence in studies that have found a difference, such as the Cache County Memory Study, suggest that longevity remains an important reason why there are more women with AD than men. The complications in estimating incidence and the increasing body of clinical and preclinical evidence supporting sex-specific biological mechanisms in diverging AD risk remain an important adjunct explanation to the epidemiologic perspective and should be investigated more closely in future studies. Table 1 summarizes most representative studies investigating sex differences in humans collected from 2000 to date.
Biological perspective
It is interesting to note that women tend to develop diseases associated with senescenceedefined as reduced function due to agingeat earlier ages than men, especially for diseases that are notorious for resulting in increased morbidity but rarely lead directly to mortality (Graves et al., 2006) . In addition, women consistently have a higher age-specific prevalence of disability globally (Buttery et al., 2016; Crimmins et al., 2011; Freedman et al., 2016; Jagger et al., 2016; Wahrendorf et al., 2013; Whiteford et al., 2015) . It is therefore very likely that similar trajectories are present for the development of cognitive deficits due to diseases with low-or late-stage mortality. The potential for a real increase in AD incidence among women may be part of this trend toward rapid senescence and disability, and many of the biological mechanisms proposed to explain this global, age-related reduction in functionality also extend to the development of AD. In the following sections, we review some of the prevailing biological mechanisms that may explain the increased incidence of AD in women reported in some studies, drawing on both clinical and preclinical studies from the literature.
3.1. Sex and genetics interaction in AD: focus on ApoE and BDNF 3.1.1. ApoE
As more genomic studies uncover risk genes for various diseases, there have been more instances of differing risk profiles for a particular genomic variant between sexes (Gatz et al., 2006; Riedel et al., 2016) . In line with this, recent epidemiologic studies demonstrated that the APOE allele confers different AD risk profiles based on sex. These studies indicate that women with APOE-ε4 are at greater risk for developing AD than age-matched men, especially when comparing heterozygous individuals carrying the APOE-ε4 allele Damoiseaux et al., 2012) . In a large meta-analysis (Farrer et al., 1997) and in a large population study of AD (Bremner, 1999) , women who were heterozygous for the APOE-ε4 allele had AD diagnosed 5 years earlier than heterozygous men (Poirier et al., 1993) . Similarly, the odds ratio for AD in women with one copy of the APOE-ε4 allele is 4-fold greater than in men Farrer et al., 1997; Payami et al., 1994) . In addition, women carrying ε3/ε4 often show faster age-related decline and greater cognitive deterioration than age-matched ε3/ ε4 men (Beydoun et al., 2012; Farrer et al., 1997) . However, one study found that the association between the APOE genotype and cognitive decline is significant only in women aged greater than 70 years (Mortensen and Hogh, 2001) , whereas a recent meta-analysis suggested women with 1 copy of APOE-ε4 only had higher risk in the age range of 65e75 years (Neu et al., 2017) , and therefore, more research is needed to determine the impact of this sex-by-gene interaction.
In support of these clinical findings, preclinical investigations of AD mouse models have revealed similar sex-by-APOE interactions for AD-like pathology and cognitive deficits. Notably, 1 study demonstrated that female 3xTg-AD mice with neural expression of the human APOE-ε4 showed increased spatial memory deficits compared to APOE-ε4 male mice or APOE-ε3 males and females starting at 6 months of age (Raber et al., 1998) .
Paradoxically, men homozygous for APOE-ε4 are reported to be at greater risk for MCI and AD in some studies than homozygous women, with men in these studies demonstrating a shift to lower episodic memory scores (Farrer et al., 1997; Lehmann et al., 2006) . In conjunction, one report noted that men who are APOE-ε4 homozygotes with MCI have smaller hippocampal volumes than homozygous women (Fleisher et al., 2005) . These discrepancies between sexes for AD risk in the homozygous and heterozygous states complicate the interpretation of the sex-by-gene interactions concerning the APOE-ε4 allele.
APOE's influence on AD pathogenesis is multifaceted and likely includes regulation of Ab clearance, tau phosphorylation, cerebrovascular permeability, bloodebrain barrier integrity, inflammatory responses, and synaptic maintenance (Bu, 2009 , Tai et al., 2016 . It is tempting to speculate that the heterozygotes may suffer more from abnormal Ab production and clearance, whereas the homozygotes have increased dementia pathogenesis from impaired cardiovascular function (Liu et al., 2013) and, thus, may affect men and women differently. However, a more detailed understanding of APOE's role in AD pathogenesis is essential to discovering why such divergent risk profiles by sex are apparent in APOE-ε4 carriers.
BDNF
The neurotrophin BDNF is an important factor controlling synaptic plasticity in the CNS (Kowia nski et al., 2017) , and many neuropsychiatric diseases have demonstrated changes in BDNF in their pathogenesis or treatment, especially mood disorders (Yeh et al., 2015) . Recently, certain BDNF polymorphisms in humans have been shown to affect the risk of AD development and cognitive decline (Li et al., 2017a ,b, Chen et al., 2014 Fukumoto et al., 2010; Lim et al., 2015; Matyi et al., 2017) , and AD patients have been reported to have decreased BDNF in postmortem brain samples (Li et al., 2017a,b) and peripherally in blood (Qin et al., 2017) . Similar to APOE, many of these association studies discovered increased risk of AD for women over men. For instance, the BDNF Val66Met polymorphism has been shown to increase AD risk only in women but not men (Chen et al., 2014; Fukumoto et al., 2010; Li et al., 2017a,b) , whereas similar findings of increased risk in only women were found for 2 other SNPs, rs2072446 and rs56164415 (Matyi et al., 2017) . In addition, one of these studies reported that while BDNF was decreased in many cortical areas in both sexes, only females demonstrated BDNF downregulation in the entorhinal cortex, a main input and output area of the hippocampus (Li et al., 2017a,b) . Preclinically, it is interesting to note that in a prominent AD mouse model, APPsw/PS1dE9, female mice had higher levels of soluble Ab and mature BDNF (mBDNF) at baseline but saw a precipitous drop in mBDNF and the mBDNF/proBDNF ratio with stress. In contrast, the male counterparts had an increase in mBDNF with chronic stress, suggesting that female mice may suffer more from a stress-by-genotype interaction in terms of BDNF loss than males.
In addition, both genetic and biochemical studies have demonstrated a link between APOE and BDNF in AD pathogenesis (Lim et al., 2015; Sen et al., 2015 Sen et al., , 2017 Ward et al., 2014) . Multiple studies have suggested that in the presence of Ab, APOE-ε4, and BDNF Val66Met worsen cognitive decline more than either allele in isolation, especially for episodic memory (Lim et al., 2015; Ward et al., 2014). Mechanistically, it has been suggested that APOE directly regulates BDNF expression and secretion (Sen et al., 2015 (Sen et al., , 2017 . It has also been shown that the APOE-ε4 causes HDAC4 and HDAC6 to translocate into the nucleus, where these deacetylases reduce BDNF expression through transcriptional repression (Sen et al., 2015) , leading to decreased BDNF creation and secretion (Sen et al., 2017) . In contrast, APOE-ε3 has little or no effect on BDNF levels (Sen et al., 2015) . Given the increasing evidence that APOE status can affect BDNF and that certain APOE and BDNF alleles may predispose women to develop AD more easily than men, a sexually divergent interaction between these AD effectors is quite possible. In general, it is also interesting to note that estrogen can influence the expression of BDNF and that many of the pathways supported by BDNF signaling are also influenced by estrogen (Scharfman and MacLusky, 2006) . However, whether estrogen plays a mechanistic role in the cross-talk between APOE and BDNF remains to be seen. While evidence demonstrating BDNF's role in AD pathogenesis continues to build, it remains unclear how BDNF alone or combined with APOE influences AD. As BDNF is a dynamic regulator of neuronal survival and synaptic plasticity (Kowia nski et al., 2017), a simple hypothesis may suggest that loss of BDNF makes neurons more susceptible to AD-related toxicity. In addition, it is possible that BDNF directly acts on AD-causing intermediates, as BDNF has been shown to reduce Ab-42 in primary neurons from AD mice through the SORLA-MEK/ERK pathway (Rohe et al., 2009 ), another pathway regulated by APOE (Bu, 2009) . Although progress has been made, future investigations will be needed to define this mechanism more clearly. Because of the ample evidence suggesting greater AD susceptibility for women with BDNF mutations, investigating sex differences should be an important part of these investigations.
3.2. Sex-specific brain structure changes and biomarkers in AD One explanation for the sexual dimorphism in AD risk and severity centers on the divergent changes in brain structures that men and women have in response to disease or disease-causing insults. It is posited that women may be more sensitive to pathologic agents for AD and experience more rapid structural loss when compared to their male counterparts, who are posited to have a larger cognitive reserve based on increased brain volume (Mielke et al., 2014) . Many examples of this are apparent in the literature.
As part of the Alzheimer's Disease Neuroimaging Initiative, a study examined 1-year atrophy rates using 3D-tensorebased MRI morphometry in 1368 MRI scans (144 subjects with AD, 338 subjects with MCI, and 202 controls), it was discovered that annual atrophy rates were faster in women (Hua et al., 2010) . A follow-up study further showed that women with MCI had greater atrophy in numerous brain regions and a steeper decline in certain cognitive tasks compared to men, as well as greater atrophy in numerous regions once an AD diagnosis had been made (Holland et al., 2013) . In the Minimal Interval Resonance Imaging in AD study, women with probable AD demonstrated significantly faster rates of hippocampal atrophy than their male counterparts (Ardekani et al., 2016) . On a molecular level, another study used discovery driven quantitative proteomics to detect modulation of several redox proteins in the temporal lobe of patients with combined AD and cerebrovascular disease (AD þ CVD subjects) and observed sexspecific alterations in the white matter and mitochondrial proteomes in women. Female patients also displayed downregulation of certain ATP synthase and cytochrome oxidase subunits, suggesting increased severity of mitochondrial impairment in women with AD þ CVD (Gallart-Palau et al., 2016) . These studies suggest that when degeneration begins, it may affect women more rapidly than men, resulting in the observed increase in pathophysiology.
In concert, a clinicopathological study observed a large sex difference in the association of AD pathology with the odds of AD dementia in men and women. Specifically, it was reported that each additional unit of AD pathology was associated with a nearly 3-fold increase in the odds of AD dementia in men compared with a more than 22-fold increase in the odds of AD dementia in women (Barnes et al., 2005) , again suggesting that women might possibly be more sensitive to the pathologic agents that cause AD. In agreement, a recent study reported that women with higher CSF Ab-42 and total tau levels, indicative of worse pathologic changes, showed more rapid hippocampal atrophy and cognitive decline than men, furthering the notion that divergent responses in structural integrity to pathologic insults are based on sex in AD (Koran et al., 2017) .
Although the current studies seem to be in agreement in regard to divergent structural responses to pro-AD agents, it is difficult to conclude whether the observed sex difference is driven by differences in the etiology and pathophysiology of the AD cascade or the late-life risk factors of poor brain aging. Furthermore, although these structural changes are readily observed, the underlying molecular mechanism leading to this divergence is still far from clear.
Impact of differing sex hormones in AD
Changes in sex steroid hormones (i.e. estrogen and progesterone in females and testosterone in males) have been associated with AD onset and progression, representing an endocrinological explanation for AD risk (Grimm et al., 2016) . Among these sex hormones, estrogen has received the most attention in clinical and preclinical investigations. Although much of the body's estrogen is synthesized in the ovaries, a significant amount is also produced in the CNS, where 1 of the 3 isoforms of estrogen, E2 and its receptor (ER), has been observed in high levels in limbic system regions, such as the hypothalamus and hippocampus (Cui et al., 2013) . E2 has been shown to mediate sex-specific behaviors, regulate synaptic plasticity, and promote neural survival in a number of studies (Green and Simpkins, 2000) . Because of its neuroprotective role, the rapid decrease in endogenous estrogen levels during menopause has been proposed as a trigger for the development of AD in females (Paganini-Hill and Henderson, 1994) . However, only a few studies have shown a direct link between estrogen and AD. One clinical study from the Mayo Clinic, the Cohort Study of Oophorectomy and Aging, showed an almost 2-fold increase in dementia risk in women who underwent bilateral oophorectomy before menopause (Rocca et al., 2011) . In the Cache County Memory Study, women who used hormone replacement therapy in the perimenopausal period had fewer cases of AD later on life (Zandi et al., 2002) . Another study found that surgical menopause was associated with a faster rate of cognitive decline and more pHF-tau pathology (Bove et al., 2014) . In support of this, 1 preclinical study demonstrated that in young APPswe mice with ovariectomies, absolute Ab levels remain similar to controls, but the Ab/sAPPa ratio significantly increases due to decreased APP. However, supplemental estrogen administered to these mice paradoxically reduced Ab levels but did not alter the total levels of APP.
These results suggest that estrogen might enhance a-secretase activity leading to increased formation of sAPPa, although the uncoupling between APP and Ab metabolism with ovarectomy and subsequent estrogen replacement complicates this conclusion (Levin-Allerhand and Smith, 2002) . Another study showed that ovariectomies in APP transgenic mice (Tg2576) increased the levels of Ab levels in the brain and that estrogen replacement therapy blocked this effect (Zheng et al., 2002) . However, the same experiments in Tg2576þPS1 double mutant mice demonstrated a much smaller effect, suggesting that differences in transgenes or strains might mediate the relative impact of estrogen in these models (Wang et al., 2003) .
The downstream mechanisms of estrogen's effect on AD neuropathology are still poorly understood, and hypotheses centering on transcriptional regulation and downstream kinase cascades have both been presented (Hwang et al., 2016; Sarkar et al., 2015) . One probable mechanism whereby estrogen is neuroprotective in AD is through shifting APP processing toward the nonamyloidogenic pathway via a-secretase through activation of extracellular-regulated kinase 1 and 2 (ERK1 and 2) and protein kinase C (Cordey et al., 2003; Wang et al., 2016) . Furthermore, estrogen may act through activation of the MARK/ERK pathway to reduce Ab levels, potentially through BACE1 inhibition and increased Ab clearance (Tamagno et al., 2009) .
But although the preclinical evidence seems to suggest a protective role for estrogen in AD pathogenesis, clinical trials concerning estrogen replacement therapy (ERT) have resulted in inconclusive data, with some even showing decreased cognitive function with estrogen-only therapies (Asthana et al., 2001; Henderson et al., 2000; Mulnard et al., 2000; Shumaker et al., 2003; Tang et al., 1996; Wang et al., 2000) . The results of these studies are surprising, although it is possible that ERT confers other risks that interact with AD pathogenesis to worsen cognition, such as those regarding cardiovascular health. Furthermore, it remains unclear if estrogen þ progesterone or progesterone alone may have different neuroprotective properties in postmenopausal women compared to those who took ERT. Finally, some preclinical studies have suggested that estrogen may be an important factor in preventing AD during certain "critical windows," which is supported by association data in the Cache County Memory Study (Zandi et al., 2002) . One preclinical study suggested that ERT had a higher likelihood of being neuroprotective in the perimenopausal but not postmenopausal period (Christensen and Pike, 2017) . Intriguingly, another study noticed an increase in Ab and poorer working memory in female AD mice compared to males that could be reversed by supplementing neonatal females with testosterone propionate, resulting in brain masculinization (Carroll et al., 2011) and suggesting that early exposure to sex hormones during development may have a large impact on later life AD risk. Still, whatever the reason for the disconnect between preclinical and clinical studies, the role of estrogen in AD pathogenesis is likely to be more complex than originally perceived. Interestingly, studies in human patients and animal models suggest that androgen deprivation may also represent a risk factor for AD pathogenesis in males (Pike et al., 2009; Rosario et al., 2010; Verdile et al., 2014) . One study demonstrated that brain testosterone levels were inversely correlated to soluble Ab concentration in men (Rosario et al., 2011) . Another preclinical study indicated that increased testosterone in aged male 3xTg-AD mice was correlated with reduced Ab plaque pathology (Overk et al., 2013) , suggesting a role for testosterone in amyloid processing or clearance. These data were supported by findings where testosterone altered APP processing (Goodenough et al., 2000) . Despite these interesting data points, there still remains only a few studies to date that have investigated androgens' role in AD pathogenesis, and so closer investigations are likely warranted.
In summary, while an endocrinological basis of AD risk is likely to exist, the significance of these declining sex hormones with age is relatively unclear. For instance, although estrogen seems to be neuroprotective in rodent models, ERT in humans was unable to improve cognition or delay AD onset. Regardless of the impact of sex hormones on AD, it is very likely that subtle second messenger system alterations between sexes underlie and likely unify many of the observed increases in AD risk for women when viewed at the genetic (APOE, BDNF), structural, or hormonal levels. In agreement with this, it has been observed that sexually dimorphic second messenger signaling is evident for certain GPCRs and may increase AD risk in a sex-specific manner (Bangasser et al., 2017) . One of the most salient examples of this is discussed in Section 3.5.
Sexual dimorphism in immune function and the link with AD
While Ab and hyperphosphorylated-tau are considered to be the pathogenic intermediates underlying AD, their interaction with the immune system has garnered a lot of attention. Recently, many immune function genes that are expressed in microglia have been identified in GWAS studies investigating genetic causes of AD risk, including TREM2 (Guerreiro et al., 2013; Wang et al., 2015) , CR1 (Lambert et al., 2009) , CLU (Harold et al., 2009; Lambert et al., 2009) , and CD33 (Bradshaw et al., 2013; Griciuc et al., 2013) . In addition, a recent gene-network analysis implicated immune and microglial dysfunction as the leading perturbed pathway in AD in human patients, a result which was specific to AD and not found in other neurodegenerative disorders, such as Huntington's Disease (Zhang et al., 2013) . In line with this, it has been found that elevation of certain cytokines in plasma are correlated with dementia development or conversion from MCI to AD, and imaging studies have found that increased microglial activation is a better predictor of cognitive decline than Ab load (Buchhave et al., 2010; Cagnin et al., 2001; Edison et al., 2008; Engelhart et al., 2004; Holmes et al., 2009; Jin et al., 2008; Laurin et al., 2009; Patel et al., 2005) .
Microglia play an active role in both Ab regulation and immunologic response . As evidence accumulates showing that persistent immune dysregulation affects AD development, numerous studies have demonstrated specific mechanisms whereby microglia may mediate neural degeneration and cognitive dysfunction Ji et al., 2013; Lenz and McCarthy, 2015) . Of these mechanisms, microglial regulation of synapses may be the most important for AD. It has been shown that the degree of synaptic degeneration is a much better predictor of cognitive decline in AD than Ab levels, as degeneration of these synaptic structures syncs up more closely with symptom development and precedes neuronal loss (DeKosky and Scheff, 1990; Hong et al., 2016; Lue et al., 1996; Mucke and Selkoe, 2012; Terry et al., 1991) . These findings are in line with the hypothesis that chronic Ab toxicity primes microglia, causing them to respond more readily to local environmental changes with cytokine release and enhanced pruning of synapses Holmes, 2013; Perry and Holmes, 2014) .
Given the role for the immune system in AD development, it is important to note that females have a propensity toward greater immune reactions than men. First, males tend to develop infections more readily than females (Klein, 2000) , and females tend to have a more robust immune response in the form of greater antibody production and a greater propensity toward TH1 responses (Amadori et al., 1995; Hanamsagar and Bilbo, 2016; Kivity and Ehrenfeld, 2010; Kovacs et al., 2002) . In addition, estrogen generally enhances the immune system at low doses while androgens tend to be more immunosuppressive (Hanamsagar and Bilbo, 2016; McClelland and Smith, 2011) . At the level of the brain, males tend to have more microglia early in development while females tend to have many more microglia from early adulthood onward (Lenz and McCarthy, 2015; Schwarz et al., 2012) .
Perhaps most interestingly, however, is the fact that about 80% of patients with autoimmune disorders are women (Cooper and Stroehla, 2003; Gleicher and Barad, 2007; Kivity and Ehrenfeld, 2010) , (Hanamsagar and Bilbo, 2016) , suggesting that women may have more primed immune systems and thus more readily exhibit heightened immune responses. In support of this, one study found that while children of women with autoimmune disorders often developed autoimmune diseases, they were rarely the same disease exhibited by the mother (Gleicher and Barad, 2007) . This is an important point, as it may explain why AD is not necessarily associated with other autoimmune diseases, since AD patients may manifest disease due to common immunological priming while expressing divergent pathophysiology to specific insults.
Finally, the interaction between stress and the immune system is different between men and women. Specifically, it was shown that while glucocorticoid signaling, which is a main mediator of the vertebrate stress response, induced apoptotic pathway upregulation in male hepatic cells, female hepatic cells tended to upregulate IL-6erelated pathways, which are proinflammatory (Deak et al., 2015) . Furthermore, glucocorticoid signaling tends to be higher in females at baseline, and estrogen has been shown to increase glucocorticoid release while androgens decrease it (Gaillard and Spinedi, 1998) . Interestingly, when challenged with a lethal dose of the immunogen LPS, the corticosteroid dexamethasone was able to prevent death in male rats at low doses while much higher doses were needed for females (Deak et al., 2015) , demonstrating that the female immunosuppressive response to glucocorticoids is less potent than males.
Still, while AD is likely to be affected by immune system function and while ample evidence suggests very different inflammatory responses between sexes, whether these divergent responses lead to a difference in AD susceptibility is unclear. For one, even the role of sex in autoimmune disease pathogenesis is unknown, with hypotheses describing differences in sex hormones, X-inactivation patterns, and gene dosing, and microchimerism all having evidence supporting and diminishing their likelihood as being the underlying mechanism (Gleicher and Barad, 2007; Kivity and Ehrenfeld, 2010; Selmi, 2008) . Future studies demonstrating an immune system and sex interaction in AD pathogenesis would be needed, and rigorous hypothesis-based testing would be essential to confirm if any of the mechanisms potentially leading to increased autoimmunity also lead to increased AD risk in women.
Stress and sex-specific CRF signaling in AD
Clinical evidence has suggested a link between psychosocial stress and AD going back at least 2 decades. Stress-related increases in plasma cortisol levels (Swanwick et al., 1998; Rehman, 2002; Umegaki et al., 2000) and correlations between increased cortisol levels and the severity of cognitive decline (Csernansky et al., 2006; Pedersen et al., 2001 ) have been reported in AD. These changes in the hypothalamus-pituitary-adrenal (HPA) axis do not appear to be secondary to MDD, as AD patients with and without MDD have higher cerebrospinal fluid cortisol levels compared to controls (Hoogendijk et al., 2006) . In support of this, the centrally active stress response receptor corticotropin releasing factor 1 (CRF1) is also increased in the hippocampi of AD patients (Behan et al., 1995 , and HPA axis changes have been associated with hippocampal atrophy (O'Brien et al., 1996) . Furthermore, many abnormal behaviors, termed Behavioral and Psychosocial Symptoms in Dementia, occur at an alarmingly high rate in AD patients, and at least some of these abnormal behaviors can be attributed to alterations in stress hormone signaling (Reisberg et al., 1987) . In line with these human studies, transgenic mouse models have recapitulated at least some of the neuropathological and behavioral changes associated with AD and thus provide an opportunity to investigate how the different biochemical markers underlying the psychosocial stress response and AD pathogenesis interact in vivo (Campbell et al., 2015; Carroll et al., 2011; Cuadrado-Tejedor et al., 2012; Dong et al., 2004 Dong et al., , 2008 Green et al., 2006; Jeong et al., 2006; Kang et al., 2007; Rissman et al., 2012) .
Women are more susceptible to stress-influenced diseases, and it is possible that sexually dimorphic stress responses could greatly influence the difference between men and women in the rate of AD conversion and progression. Although clinical evidence demonstrating an interaction between sex and stress in AD development remains scarce, an intriguing study demonstrated that women with mild-to-moderate AD have significantly increased levels of cortisol production compared to their male counterparts (Rasmuson et al., 2011) , although these data could not establish causation.
Although studies in humans are limited, preclinical studies have also shown a sex-specific difference in AD pathogenesis under psychosocial stress (Sierksma et al., 2012) . For instance, 5-day restraint stress (6 h/d) in 5XFAD transgenic mice leads to increased levels of neurotoxic Ab42 peptides, b-secretaseecleaved C-terminal fragment (C99), and plaque burden in the hippocampus of female but not male mice at a time point before severe AD-like behavioral deficits are observed. Moreover, sex-and brain regionespecific accelerations in b-amyloidosis are accompanied by elevations in BACE1, APP, and phosphorylated EIF2a in response to psychosocial stress (Devi et al., 2010) . Also, environmental stress preferentially triggers memory impairments in female but not in male P301L-tau mice (Sotiropoulos et al., 2015) . Furthermore, in this model, stressrelated increases in caspase-3etruncated tau and insoluble tau have been found to aggregate exclusively in the female hippocampus (Sotiropoulos et al., 2015) . Potentially driving this effect, the expression of the molecular chaperones Hsp90, Hsp70, and Hsp105 were altered to favor accumulation of tau aggregates (Sotiropoulos et al., 2015) . Although some ambiguity exists between these studies regarding the interaction between stress and sex, it seems likely that both are impacting disease pathogenesis.
As mentioned, the exact stresseresponse molecules that mediate increased AD pathogenesis are still unknown, though data confirming an important hypothesis implicating central CRF1 signaling in this process is emerging. Increased CRF1 signaling has been associated with multiple stages of APP proteolysis, regulation of Ab generation, and Ab-mediated toxicity (Thathiah and De Strooper, 2011; Thathiah et al., 2013) , and GPCR signaling in general has been suggested as a novel target for AD drug development (Femminella et al., 2013; Wolfe, 2013) . Importantly, CRF overexpression in the forebrain can lead to accumulation of Ab and tau phosphorylation through CRF1-Gs-PKA signaling, consistent with Gs-PKA signaling's role in influencing the amyloid production cascade through modulation of a-, b-, and g-secretases (Park et al., 2015; Robert et al., 2001; Thathiah and De Strooper, 2011; Thathiah et al., 2013; Xu et al., 1996) . Specifically, while transient activation of these signaling cascades shifts APP metabolism toward the a-secretaseemediated pathway that results in nonpathogenic amyloids, chronic activation shifts APP metabolism to the b-, g-, and perhaps also the h-secretaseemediated pathways that result in increased pathogenic Ab generation (APP-CTF99, A-beta 40, and A-beta 42). (da Cruz e Silva et al., 2009 , Willem et al., 2015 . In addition, PKA signaling is associated with tau phosphorylation, another molecular pathway that is highly implicated in AD pathogenesis (Blanchard et al., 1994 , Sanchez-Mut et al., 2014 . Thus, there is much evidence implicating CRF1 signaling as the causative pathway facilitating psychosocial stress' detrimental effects on AD pathogenesis.
When taken together with the evidence that prolonged CRF signaling through CRF1 results in sexually dimorphic second messenger activation, a potential mechanism begins to take shape: Because Gs-PKA signaling is central to the formation of ADcausative amyloids and phospho-tau, and there exists a bias toward CRF1-Gs-PKA signaling in females, this signaling pathway may provide a functional link between these 2 processes and begins to create a unified, biologically driven explanation for why women develop AD more readily than men. Still, this hypothesis is based on Immortalized rat hypothalamic cell line (GT1-7) N/A Androgens Testosterone was found to increase the amount of APP secretion rapidly after treatment without effecting the overall amount of cellular APP. The species of APP secreted was found to be predominantly the product of the nonamyloidogenic alpha-secretory pathway.
Furthermore, this event is regulated via aromatase-mediated conversion of testosterone to estrogen and the mitogen-activated protein kinase (MAP kinase) signaling pathway.
The articles in black color indicate studies supporting females more vulunable to neuropathgenesis of AD and those in shaded region oppose those findings.
evidence from a combination of isolated experiments that only suggest this mechanism, but rigorous and direct testing of this hypothesis will need to be specifically undertaken to assess whether it is a suitable explanation for what is observed in AD patients. In addition, how CRF1 signaling and peripheral glucocorticoid signaling interact is still unknown in terms of increased AD risk, and experiments specifically targeting one or the other are needed to see if an interaction between the 2 is necessary for the increased risk of AD. Table 2 summarizes the studies on sex difference in AD with animal models, collected from 2000 to date.
Conclusion
An explanation for the apparent difference in the rate of AD diagnoses between men and women remains elusive, but more and more evidence is beginning to suggest that a true increase in risk is complementing the epidemiologic explanations describing the increased female prevalence for the disease. Importantly, biological mechanisms that are intrinsic to women are increasingly prominent in the literature. Specifically, those involving age-related changes in sex hormone signaling, sexual dimorphism in neural structures, gene-by-sex interactions, female-specific increases in immune responses, and the interaction between sex and stress have been gaining traction as important determinants of AD. Still, much remains to be described before adopting any of these potential explanations as drivers of disease, and certainly a greater understanding of the biology underlying these mechanisms is warranted before therapeutic development should be undertaken. The ERT trials stand as a sobering testament to that fact. It seems clear that more detailed studies using preclinical animal models to explore these molecular explanations will begin to unravel the mystery concerning the increased risk of AD in women, and the promise of future therapeutics through this line of investigation remains high.
One of the most important outstanding questionseand perhaps the largest "elephant in the room"eis why so many studies have suggested the presence of female-specific, biological risk factors and why so few studies have uncovered a difference in incidence between sexes. As described in length previously, difficulties in correct classification of AD remain one potential source of ambiguity, but this alone is unlikely to be the sole source of bias. What remains a possibility is that prospective cohort studies and metaanalyses have been insufficiently powered to detect a difference, as seen in the Fiest et al., 2016 meta-analysis which consistently detected higher prevalence and incidence rates for women without reaching statistical significance. Although a significant undertaking, a large, prospective cohort study with postmortem confirmation of AD would be immensely helpful in resolving this issue.
Finally, as we move toward "personalized medicine," improving our understanding of sex-specific disease mechanisms will be one of the first areas to yield substantial improvements in prevention and treatment outcomes across all branches of medicine. But, it is important to note that investigations of sex-specific risk are just as likely to reveal central mechanisms of disease pathogenesis that are independent of sex. By careful comparison and inclusion of both sexes in preclinical and clinical research, upstream and downstream pathways that converge in both sexes will point the way toward shared mechanisms resulting in disease pathogenesis and severity. Exploiting these commonalities is more likely to lead to successful interventions and treatments than ignoring sex as a potential risk factor, as careful consideration of disease pathogenesis by sex will reduce sex-specific motifs that are mistaken as being causative but are in truth epiphenomenal. Therefore, although improving our understanding of underlying sexual dimorphism in AD risk will be critical for developing treatments that are especially effective in women, this line of research also has the potential to reveal new targets for the treatment of AD and other neurodegenerative disorders in both sexes.
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